{
    "clinical_study": {
        "@rank": "137693", 
        "arm_group": {
            "arm_group_label": "Patients with Chronic Migraine Prescribed BOTOX\u00ae", 
            "description": "Onabotulinumtoxin A (BOTOX\u00ae) administered according to physician prescription; all treatment decisions lie with the physician."
        }, 
        "brief_summary": {
            "textblock": "This is an observational study to describe the long term use of Onabotulinumtoxin A (BOTOX\u00ae)\n      as prescribed by the physician for headache prophylaxis in adults with chronic migraine.\n      All treatment decisions lie with the physician."
        }, 
        "brief_title": "An Observational Study of BOTOX\u00ae as Headache Prophylaxis for Chronic Migraine", 
        "completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Migraine Disorders", 
        "condition_browse": {
            "mesh_term": "Migraine Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Prescribed BOTOX\u00ae for the prophylaxis of headaches\n\n        Exclusion Criteria:\n\n          -  Received treatment with any botulinum toxin Type A serotype in the last 26 weeks\n\n          -  Current participation in Allergan's Botox Chronic Migraine Post-Authorisation Safety\n             Study (protocol 191622-110)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with chronic migraine prescribed BOTOX\u00ae for the prophylaxis of headaches"
            }
        }, 
        "enrollment": {
            "#text": "1400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01686581", 
            "org_study_id": "MAF/AGN/NS/CM/002"
        }, 
        "intervention": {
            "arm_group_label": "Patients with Chronic Migraine Prescribed BOTOX\u00ae", 
            "description": "Onabotulinumtoxin A (BOTOX\u00ae) administered according to physician prescription; all treatment decisions lie with the physician.", 
            "intervention_name": "Onabotulinumtoxin A", 
            "intervention_type": "Drug", 
            "other_name": "BOTOX\u00ae"
        }, 
        "intervention_browse": {
            "mesh_term": "Botulinum Toxins, Type A"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kiel", 
                        "country": "Germany"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oviedo", 
                        "country": "Spain"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Anlaby, Hull", 
                        "country": "United Kingdom", 
                        "state": "East Yorkshire"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "Spain", 
                "Sweden", 
                "United Kingdom"
            ]
        }, 
        "number_of_groups": "1", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Ethics Commission", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Healthcare Resource Utilization Using a Patient Questionnaire", 
            "safety_issue": "No", 
            "time_frame": "24 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01686581"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "EuroQol Group EQ-5D Questionnaire Score", 
                "safety_issue": "No", 
                "time_frame": "24 Months"
            }, 
            {
                "measure": "Headache Frequency", 
                "safety_issue": "No", 
                "time_frame": "24 Months"
            }, 
            {
                "measure": "Patient Treatment Satisfaction Using a 4-Point Scale", 
                "safety_issue": "No", 
                "time_frame": "24 Months"
            }, 
            {
                "measure": "Migraine Specific Quality of Life Questionnaire (MSQ) Score", 
                "safety_issue": "No", 
                "time_frame": "24 Months"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}